Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Evrysdi
Pharma
Biogen to seek approval for high-dose version of Spinraza
Biogen said that a portion of its DEVOTE study met its primary endpoint, as a higher dose of Spinraza improved the motor function of infants with SMA.
Kevin Dunleavy
Sep 4, 2024 11:45am
Royalty commits up to $1.5B for most of PTC's Evrysdi royalties
Oct 19, 2023 11:13am
Genentech doubles up on Double Take, rebooting SMA fashion event
Jun 6, 2023 7:55am
With big discounts, 100+ drugs win national coverage in China
Jan 18, 2023 2:30pm
Roche pads case for Evrysdi in previously treated SMA patients
Oct 12, 2022 11:13am
Genentech wants people to do a double take when it comes to SMA
Sep 15, 2022 10:20am
